Announcements Trials
Browse Landscape

Status

Active not recruiting 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 84Observational 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 2Neoplasm, Residual 1Neoplasm Metastasis 1HER2-positive Breast Cancer 1

Interventions

Surveys and Questionnaires 53Blood Specimen Collection 53Specimen Handling 28Radiotherapy 18Observation 18Interviews as Topic 13Magnetic Resonance Spectroscopy 12Surgical Procedures, Operative 10Drug Therapy 10Data Collection 10Biopsy 10Tomography, X-Ray Computed 9darolutamide 8Watchful Waiting 7Standard of Care 7ribociclib 6palbociclib 6Restraint, Physical 6Patient Reported Outcome Measures 6Magnetic Resonance Imaging 6Immune Checkpoint Inhibitors 6trastuzumab deruxtecan 5Positron-Emission Tomography 5Mass Screening 5Genetic Testing 5Esophagectomy 5Breath Tests 5Bevacizumab 5enzalutamide 4apalutamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Trastuzumab × 90 days × Clear all
NCT06663787 2026-05-13

HER2 CR

Nagoya City University

Active not recruiting
50 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasm, Residual

NCT03738553 2026-05-04

Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy

University of Washington

Terminated
13 enrolled
Breast

HER2-positive Breast Cancer

NCT04158258 2026-04-23

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Hoffmann-La Roche

Active not recruiting
2,907 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡